Group 1 - Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation, focusing on their responsibilities to shareholders and corporate governance obligations [1] - The investigation follows a court ruling from November 5, 2024, which allowed certain claims in a shareholder class action lawsuit to proceed, alleging that Masimo misrepresented the financial performance of Sound United and misled investors about the integration process [2] - Current or long-term shareholders of Masimo Corporation may have legal claims that could be pursued against its leadership to protect and recover shareholder value [3] Group 2 - Johnson Fistel, PLLP is a nationally recognized shareholder rights and securities litigation firm, representing both individual and institutional investors across multiple states [4]

Summary of Massimo's Conference Call Company Overview - **Company**: Massimo - **Industry**: Medical Supplies and Devices - **Key Personnel**: Katie Seisman (CEO), Micah Young (CFO), Matt Taylor (Analyst) Core Company Evolution - Massimo has transitioned from a parameters company focused on pulse oximetry to a solutions company with a broader portfolio [2][3] - The company has been a market leader in pulse oximetry with approximately 55% market share in the US and 50% globally [5][9] - Recent acquisitions include capnography, brain monitoring, hemodynamics, and automation technologies [4][5] Market Dynamics and Growth Potential - The pulse oximetry market is expected to grow in the low single digits, with Massimo gaining 1-2 percentage points of market share annually [9][10] - The introduction of AI-based algorithms for detecting conditions like atrial fibrillation is anticipated to enhance value for hospitals and drive market share growth [10] - Current monitoring penetration in general hospital floors is estimated at 20-30%, with expectations for growth as hospitals seek to monitor more patients [12][13] Financial Performance - Q1 revenue growth was reported at 10.5%, with consumables growing by 8% and capital revenue by 32% [18][19] - The company expects higher consumable orders in the upcoming quarters, despite a lighter order in Q1 due to timing [21][22] - Guidance for overall growth is set at 8-11%, with consumables expected to grow in the double-digit range [24][25] Adjacent Markets - Massimo's adjacent markets (capnography, brain monitoring, hemodynamics, and automation) are valued between $1.5 billion to $2 billion and are growing in the high single digits [14][15] - The company aims to achieve similar market share in these segments as it has in pulse oximetry [15] Cybersecurity Incident - A recent cybersecurity incident impacted operations but was resolved quickly, with no expected long-term effects on demand or guidance [40][44] Tariff Impacts - Tariffs have had a financial impact, with a potential recovery of costs due to recent changes in tariff rates from China [46][47] - The company is exploring vertical integration and qualification for US-based content to mitigate tariff exposure [49][50] Future Outlook - Massimo plans to leverage its significant installed base and introduce next-generation monitors with AI capabilities to drive growth [54][56] - The company is open to partnerships or settlements regarding ongoing litigation with Apple, focusing on protecting its intellectual property [59][63] - Future capital allocation will focus on tuck-in technology deals, wearable solutions, and AI algorithms to enhance growth [66][67] Conclusion - Massimo is positioned for continued growth in the medical supplies and devices industry, with a strong focus on innovation, market share expansion, and strategic capital allocation. The leadership team expresses confidence in the company's future trajectory and operational resilience.

Core Viewpoint - Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation in relation to their obligations to shareholders [1] Group 1: Legal Investigation - The investigation is focused on claims that Masimo's Chief Financial Officer and other executives may have inflated Sound United's financial performance and misled investors regarding its integration [3] - A court ruling on November 5, 2024, partially granted and partially denied Masimo's motion to dismiss a shareholder class action lawsuit, allowing claims against the CFO to proceed while dismissing claims against other executive defendants [3] Group 2: Shareholder Rights - Current shareholders of Masimo Corporation may have legal claims that can be brought on behalf of the company against its directors and officers [2] - Shareholders who have continuously owned MASI shares are encouraged to join the investigation through a provided link [3]

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年5月6日，迈心诺 Masimo （纳斯达克代码：MASI）发布第一季度业绩报告， 股 价在第一季度业绩超出一致预期的情况下仍出现下跌。 在Masimo发布盘后收益报告的次日，MASI的股价在 当日中午交易时 下跌超过5%，每股跌至152.84美元。 该公司计划将其Sound United消费音频业务以约 3.5亿美元 的价格出售给哈曼 国际（Harman International）。 BTIG分析师Marie Thibault、Sam Eiber和Alexandra Pang对该交易持积 极看法。 # 业绩数据 截至2025年3月29日的三个月内，公司亏损 1.707亿美元 （约合人民币12.3亿） ， 相当于每股亏损3.12美元，销售额为3.72亿美元。 尽管销售额增长了9.5%，但Masimo的净利润大幅下滑至亏损状态。 | | Q1 2025 | Q1 202 ...

Summary of Masimo's Conference Call Company Overview - **Company**: Masimo - **Industry**: Medical Devices Key Points and Arguments Leadership and Strategic Focus - Masimo is undergoing a leadership transition with a new CEO, aiming to realign and optimize its cost structure while focusing on core growth areas within hospital settings [2][4] - The company plans to concentrate on its flagship product, pulse oximetry, which accounts for over 70% of revenues, alongside growth in rainbow hemodynamics, brain monitoring, capnography, gas monitoring, and automation [2][3] Financial Performance and Growth Expectations - Masimo expects a long-term revenue growth of 7% to 10% with aspirations to achieve 30% operating margins [4] - In Q1, capital growth was reported at 32%, significantly higher than the expected flat to mid-single-digit growth, attributed to a large tender order from a long-term customer [8][9] - Consumable growth is anticipated to be in the high single-digit to low double-digit range, with Q1 showing strong underlying growth despite some lumpiness in orders [10] Operational Challenges and Cyber Incident - The company is recovering from a cyber incident, with critical systems being prioritized for restoration. There is no expected impact on annual guidance, although some near-term disruptions are anticipated [15][17] - The company is quantifying the cost impact of the cyber incident, with insurance expected to cover a significant portion of the expenses [19] Tariffs and Cost Management - Masimo sources about 5% of its cost of goods from China, with a potential reduction in tariff exposure due to recent changes in tariff rates [26][27] - The company is focusing on cost mitigation strategies, including pricing adjustments and optimizing supply chains, particularly in Mexico and Malaysia [32][35] Margin Expansion and Future Outlook - Operating margins in Q1 were reported at 28.8%, with a goal to maintain margins between 28% and 28.5% for the year [41] - The long-term goal is to achieve gross margins closer to 66%, with aspirations for 70% despite setbacks from COVID-19 and inflationary pressures [40][43] Litigation Updates - Ongoing litigation with Apple includes patent infringement cases, with significant developments expected in the coming months [52][54] Capital Deployment Strategy - The company plans to prioritize share buybacks and improve liquidity while evaluating opportunities for tuck-in technologies to enhance its core business [48][49] Conclusion - Masimo is optimistic about its position for the year, emphasizing strong fundamentals and a commitment to margin expansion and reinvestment for growth [56][57]

Core Viewpoint - Growth investors are focused on stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to inherent volatility and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Masimo (MASI) is currently highlighted as a recommended stock due to its favorable Growth Score and top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth seen as a strong indicator of future stock price gains [4] - Masimo's projected EPS growth for this year is 20%, significantly higher than the industry average of 14.2% [5] Group 3: Cash Flow Growth - Higher-than-average cash flow growth is essential for growth-oriented companies, allowing them to expand without relying on external funding [6] - Masimo's year-over-year cash flow growth is currently 13%, compared to an industry average of -0.4% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 10.7%, exceeding the industry average of 6.5% [7] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [8] - Recent upward revisions in Masimo's current-year earnings estimates have seen a 0.8% increase in the Zacks Consensus Estimate over the past month [9] Group 5: Overall Positioning - Masimo has achieved a Growth Score of A and a Zacks Rank of 2, indicating strong potential for outperformance based on the discussed metrics [11]

Group 1 - Samsung Electronics' subsidiary Harman International announced the acquisition of Masimo's audio business for $350 million (approximately 500 billion KRW), signaling expectations for further mergers and acquisitions by Samsung [1] - Industry experts view this acquisition as the beginning of large-scale mergers for Samsung, with potential targets in AI, automotive electronics, and biomedical equipment [1][2] - Samsung's recent shareholder meeting emphasized the importance of acquiring new technologies for sustained growth, indicating that more significant mergers may be forthcoming [1] Group 2 - In the automotive electronics sector, companies producing automotive communication and power system semiconductors are seen as primary targets for acquisition [2] - Samsung has been eyeing major automotive semiconductor companies like NXP and Infineon as potential acquisition targets, which could enhance its semiconductor foundry business [2] - The establishment of a future business planning group within Samsung aims to discover new business opportunities that align with its operational model, with a focus on biomedical devices and robotics [2]

完整早报音频，请点击标题下方小耳机收听 【理想汽车回应董事长李想6.39亿元天价年薪：说法不准确】 5月7日，理想汽车方面回应称，2024年，公司创始人、董事长兼CEO李想的税前薪酬达6.39 亿元的说法不准确。近日，市场传言李想2024年从理想汽车领取6.39亿元"天价年薪"，引发市场广泛关注。年报显示，李想2024年从理想汽车获取的税前 薪酬由三部分构成，分别是266.5万元的薪金、津贴和实物福利，16万元的退休金计划供款，以及6.36亿元的股份支付薪酬费用。 | 截至2024年12月31日止年度 | | 薪金,津贴 | | 股份支付 | 退休金 | | | --- | --- | --- | --- | --- | --- | --- | | | 袍金 | 和實物福利 | 膜金 | 薪酬費用 | 計劃供款 | 薪酬總額 | | | 人民幣 | 人民幣 | 人民幣 | 人民幣 | 人民幣 | 人民幣 | | 李想 | | 2,665 | | 636,309 | 160 | 639,134 | | 馬東輝 | - | 3,092 | 2,400 | 34,622 | 160 | 40,274 | | 李戴 ...

Masimo Corporation (MASI) delivered adjusted earnings per share (EPS) of $1.36 in the first quarter of 2025, up 56.3% year over year. The figure beat the Zacks Consensus Estimate by 9.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The adjustments include acquired intangible asset amortization, and acquisitions, integrations, divestitures, and related costs, among others.GAAP EPS for the quarter was 86 cents, up 45.8% from the year-ago period’s EPS of 59 cents.MASI’s Revenues in ...

Group 1 - Masimo announced the final agreement to sell its Sound United audio business to Samsung's subsidiary Harman International for $350 million in cash, with potential adjustments [1] - The transaction is expected to be completed by the end of this year [1]